Arkolith/Insider Trading/GTBP/Form 4

Breen Michael Martin

DirectorGT Biopharma, Inc. (GTBP) · full profile →Form 4 · filed Nov 12, 2021
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
6
3 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 25, 2021Conversion(C)10K$3.40$34K328K
Feb 25, 2021Conversion(C)40K$3.40$137K318K
Feb 16, 2021Grant(A)278K—$0278K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 25, 2021Conversion(C)30K—$00
Feb 25, 2021Conversion(C)100K—$00
Feb 16, 2021Grant(A)50K—$050K

Transaction Codes

C
Conversion of a derivative
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001654954-21-012057) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML